DE60143818D1 - Alpha-fetoprotein-peptide und ihre verwendung - Google Patents

Alpha-fetoprotein-peptide und ihre verwendung

Info

Publication number
DE60143818D1
DE60143818D1 DE60143818T DE60143818T DE60143818D1 DE 60143818 D1 DE60143818 D1 DE 60143818D1 DE 60143818 T DE60143818 T DE 60143818T DE 60143818 T DE60143818 T DE 60143818T DE 60143818 D1 DE60143818 D1 DE 60143818D1
Authority
DE
Germany
Prior art keywords
peptide
peptides
treatment
breast cancer
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60143818T
Other languages
German (de)
English (en)
Inventor
Thomas T Andersen
James A Bennett
Herbert I Jacobson
Fassil B Mesfin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLF Medical Technology Acceleration Program Inc
Original Assignee
CLF Medical Technology Acceleration Program Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLF Medical Technology Acceleration Program Inc filed Critical CLF Medical Technology Acceleration Program Inc
Application granted granted Critical
Publication of DE60143818D1 publication Critical patent/DE60143818D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60143818T 2001-06-02 2001-06-02 Alpha-fetoprotein-peptide und ihre verwendung Expired - Lifetime DE60143818D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/017748 WO2003007978A1 (en) 2001-06-02 2001-06-02 Alpha-fetoprotein peptides and uses thereof

Publications (1)

Publication Number Publication Date
DE60143818D1 true DE60143818D1 (de) 2011-02-17

Family

ID=21742615

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60143818T Expired - Lifetime DE60143818D1 (de) 2001-06-02 2001-06-02 Alpha-fetoprotein-peptide und ihre verwendung

Country Status (7)

Country Link
EP (1) EP1401467B3 (enExample)
JP (1) JP5073154B2 (enExample)
AT (1) ATE494301T1 (enExample)
AU (1) AU2001268133C1 (enExample)
CA (1) CA2449284C (enExample)
DE (1) DE60143818D1 (enExample)
WO (1) WO2003007978A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044041A2 (en) * 2001-11-20 2003-05-30 Clf Medical Technology Acceleration Program, Inc. Alpha-fetoprotein peptides and uses for imaging
EP1448593B1 (en) * 2001-11-20 2012-01-11 Albany Medical College Alpha-fetoprotein peptides and uses thereof
US7943577B2 (en) 2001-11-20 2011-05-17 Albany Medical College Alpha-fetoprotein peptides and uses thereof
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
WO2005044982A2 (en) 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20110257096A1 (en) * 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060111289A1 (en) * 2004-09-09 2006-05-25 Serometrix, Llc, Compositions and methods of using Alpha-fetoprotein growth inhibitory peptides
EA008926B1 (ru) * 2004-12-14 2007-08-31 Товарищество С Ограниченной Ответственностью "Реал Мед Компани" Способ коррекции иммунного состояния организма при анемии
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
CA3221395A1 (en) 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674842A (en) * 1994-10-26 1997-10-07 Health Research, Incorporated Growth inhibitory peptide

Also Published As

Publication number Publication date
EP1401467A4 (en) 2005-07-20
AU2001268133C1 (en) 2011-07-07
ATE494301T1 (de) 2011-01-15
EP1401467B1 (en) 2011-01-05
EP1401467B3 (en) 2014-02-26
AU2001268133B2 (en) 2008-05-15
JP5073154B2 (ja) 2012-11-14
CA2449284C (en) 2012-08-21
EP1401467A1 (en) 2004-03-31
CA2449284A1 (en) 2003-01-30
JP2004536128A (ja) 2004-12-02
WO2003007978A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
ATE494301T1 (de) Alpha-fetoprotein-peptide und ihre verwendung
EP1548032A4 (en) KDR-PEPTIDES AND VACCINES CONTAINING THEM
ATE294504T1 (de) Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DE69835279D1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
DE60232102D1 (de) Zusammensetzungen und Verfahren zur WT1-spezifischen Immuntherapie
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
SG160205A1 (en) Modified polypeptide
ATE509096T1 (de) Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
GB9924957D0 (en) Novel treatment
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
ATE435031T1 (de) Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE60019725D1 (de) Verwendung eines mit dem peptid "elagigiltv" assoziierten enterobakterien-proteins ompa zur behandlung von melanomen
DK0938329T3 (da) Immunogen TLP sammensætning
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
BR0007816A (pt) Fator de estimulação óssea
ATE540968T1 (de) Alpha-fetoproteinpeptide und deren verwendungen
FI20050753A0 (fi) Uudet peptidit
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
AU2003261102A1 (en) Novel polynucleotide and polypeptide sequences and uses thereof
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten

Legal Events

Date Code Title Description
R097 No opposition filed against granted patent, or epo opposition proceedings concluded without decision

Ref document number: 1401467

Country of ref document: EP

Effective date: 20111006

R082 Change of representative

Ref document number: 1401467

Country of ref document: EP

Representative=s name: KRAMER - BARSKE - SCHMIDTCHEN, 80687 MUENCHEN, DE